The Erector Spinae Plane Block For Gastrointestinal Malignancy Pain Treatment (EGIPT)
EGIPT
Efficacy of the Erector Spinae Plane Block for Abdominal Pain From Gastrointestinal Malignancies
1 other identifier
interventional
25
1 country
4
Brief Summary
This study will target patients with gastrointestinal (GI) malignancy who present to any of 4 Penn Medicine emergency departments (EDs) with intractable abdominal pain. We will offer eligible patients an erector spinae plane block (ESPB), a regional anesthesia technique which is already offered to such patients in the ED at the University of Pennsylvania Healthy System (UPHS), for their intractable abdominal pain. We will compare the outcomes of this prospective cohort of patients to a matched historical control of patients with GI malignancy who were treated in the ED during the same time period as recruitment, but who were not recruited to partake in the study and who were managed with standard of care. Opioid consumption as measured by total milligram morphine equivalents (MMEs) over a 24-hour period and hospital length of stay (LOS) will be compared between cohorts. Additionally, for the ESPB cohort, pain level pre/post ESPB, and functionality and satisfaction with pain management at 24 hours will also be examined.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Dec 2025
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 1, 2025
CompletedFirst Posted
Study publicly available on registry
October 8, 2025
CompletedStudy Start
First participant enrolled
December 11, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 15, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 15, 2027
November 28, 2025
November 1, 2025
1.4 years
October 1, 2025
November 24, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Opioid Consumption
We will track the amount of opioids consumed within 24 hours by patients who received the erector spinae plane block
24 hours
Opioid Consumption
We will track the amount of opioids consumed within 24 hours by participants who receive the erector spinae plane block.
24 hours
Secondary Outcomes (3)
Length of Stay
1 week
Pain Levels
30 minutes
Revised American Pain Society Patient Outcome Questionnaire
24 hours
Study Arms (1)
Treatment Arm -- Erector Spinae Plane Block
EXPERIMENTALPatients with gastrointestinal malignancy and abdominal pain will receive the erector spinae plane block for their abdominal pain.
Interventions
The abdominal viscera, from the stomach to midway through the sigmoid colon, derives its sensory innervation from afferent fibers that travel with, but are distinct from, the sympathetic nerve fibers from the 5th thoracic (T5) to the 2nd lumbar (L2) spinal levels (Moore et al). These fibers converge at the celiac plexus, located near the celiac artery and the aorta. From there, they bifurcate into the paravertebral sympathetic chain and subsequently ascend to the spinal cord and integrate into the central nervous system (Lohse et al). The celiac plexus block is an invasive procedure performed by an interventional anesthesiologist or palliative care specialist to lyse the celiac plexus and has been shown to reduce pain and opiate use in patients suffering from GI malignancy (Ashlock et al). While there are multiple methods to perform a celiac plexus block, it involves a steep needle trajectory either posteriorly through the retroperitoneum or anteriorly through the abdominal wall close
Eligibility Criteria
You may qualify if:
- Patients age \> 18 years old with GI malignancy presenting to a Penn Medicine ED with intractable abdominal pain.
- Same-day or recent CT scan of the abdomen / pelvis which demonstrates that the patient's abdominal pain can be reasonably attributed to a malignant source.
You may not qualify if:
- Allergy to ropivacaine or history of local anesthetic systemic toxicity.
- Pregnancy
- Incarcerated
- Patients being admitted for serial abdominal examinations to determine their surgical course.
- Altered mental status or inability for patient to consent for the procedure
- Hemodynamic instability
- Previously enrolled in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania, 19104, United States
Pennsylvania Hospital
Philadelphia, Pennsylvania, 19107, United States
Hospital of the University of Pennsylvania -- Cedar Avenue
Philadelphia, Pennsylvania, 19143, United States
Related Publications (2)
Gawel RJ, Kramer JA, Shalaby M. Ultrasound-Guided Erector Spinae Plane Block for Breakthrough Pancreatic and Hepatobiliary Malignancy Pain in the Emergency Department: A Case Series. Clin Pract Cases Emerg Med. 2025 May;9(2):129-133. doi: 10.5811/cpcem.39723.
PMID: 40402045BACKGROUNDForero M, Adhikary SD, Lopez H, Tsui C, Chin KJ. The Erector Spinae Plane Block: A Novel Analgesic Technique in Thoracic Neuropathic Pain. Reg Anesth Pain Med. 2016 Sep-Oct;41(5):621-7. doi: 10.1097/AAP.0000000000000451.
PMID: 27501016BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael Shalaby, MD
University of Pennsylvania Department of Emergency Medicine
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor of Emergency Medicine
Study Record Dates
First Submitted
October 1, 2025
First Posted
October 8, 2025
Study Start
December 11, 2025
Primary Completion (Estimated)
May 15, 2027
Study Completion (Estimated)
June 15, 2027
Last Updated
November 28, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share